Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

NCT ID: NCT04644016

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-20
• Study Completion Date: 2026-12-20

Brief Summary

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

Conditions

AML; ALL; MDS; MPD Withou Myelofibrosis; NHL or HL; Inherited Metabolic Disorders; Hemoglobinopathies; Bone Marrow Failure; HLH

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Participants with malignant hematologic disorders

Patients with malignant disorders receive clofarabine intravenously (IV) over 2 hours, fludarabine phosphate (fludarabine) IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or orally (PO) and mycophenolate mofetil IV over at least 2 hours in the absence of unacceptable toxicity. Patients may begin to taper tacrolimus at approximately 3 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing graft versus host disease (GVHD) requiring systemic immune suppression. TRANSPLANT: Patients undergo cord blood transplantation (CBT) on day 0.\*\*Subgroup will get rATG (day -12 to -10) POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim subcutaneously (SC) or IV over 15-30 minutes until absolute neutrophil count (ANC) recovery. Additionally, patients undergo blood sample collection, computed tomography (CT) and positron emission tomography (PET) on study.

Group Type: EXPERIMENTAL

Clofarabine

Intervention Type: DRUG

Clofarabine

Fludarabine

Intervention Type: DRUG

Fludarabine

Busulfan

Intervention Type: DRUG

Busulfan per PK

Cyclosporine-A

Intervention Type: DRUG

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Mycophenolate Mofetil

Intervention Type: DRUG

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Cord Blood Graft

Intervention Type: BIOLOGICAL

The CB graft will be infused on day 0 per standard practice

Participants with non-malignant hematologic disorders

Patients with non-malignant disorders receive rituximab IV on day -12 and rabbit anti-thymocyte globulin (rATG) over 12 hours on day -12 to -9. Patients then receive clofarabine IV over 2 hours, fludarabine IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or PO and mycophenolate mofetil IV over at least 2 hours. Patients may begin to taper tacrolimus at approximately 6 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing GVHD requiring systemic immune suppression.

TRANSPLANT: Patients undergo CBT on day 0. POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim SC or IV over 15-30 minutes until ANC recovery. Patients also receive rituximab IV on day 30.

Additionally, patients undergo blood sample collection, CT and PET on study.

Group Type: EXPERIMENTAL

Clofarabine

Intervention Type: DRUG

Clofarabine

Fludarabine

Intervention Type: DRUG

Fludarabine

Busulfan

Intervention Type: DRUG

Busulfan per PK

Cyclosporine-A

Intervention Type: DRUG

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Mycophenolate Mofetil

Intervention Type: DRUG

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Cord Blood Graft

Intervention Type: BIOLOGICAL

The CB graft will be infused on day 0 per standard practice

Interventions

Clofarabine

Clofarabine

Intervention Type: DRUG

Fludarabine

Fludarabine

Intervention Type: DRUG

Busulfan

Busulfan per PK

Intervention Type: DRUG

Cyclosporine-A

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention Type: DRUG

Mycophenolate Mofetil

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention Type: DRUG

Cord Blood Graft

The CB graft will be infused on day 0 per standard practice

Intervention Type: BIOLOGICAL

Other Intervention Names

Clolar; Fludara; Busulfex; CSA; MMF; CB graft

Eligibility Criteria

Inclusion Criteria

Age and Donor Status:

Patients with age ≤ 21 years at time of consent with no available and suitably matched related or unrelated donor in the required time period.

Diagnoses :

I. Acute myelogenous leukemia (AML) :

• Complete first remission (CR1) at high risk for relapse such as any of the following:

• Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MPS).
• Therapy-related AML (t-AML).
• White cell count at presentation > 100,000.
• Presence of extramedullary leukemia at diagnosis.
• Any unfavorable subtype by FAB or WHO classification.
• High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high-risk molecular abnormalities.
• Requirement for 2 or more inductions to achieve CR1.
• Presence of Minimal Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods after induction.
• Any patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy.
• Any patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician.
• Other high-risk features not defined above.
• Complete second remission (CR2).
• Primary refractory or relapsed AML with less than 10% blasts by bone marrow morphology. Patients with cytogenetic, flow cytometric, or molecular abnormalities in ≤ 10% of cells are eligible.

II. Acute lymphoblastic leukemia (ALL):

• Complete first remission (CR1) at high risk for relapse such as any of the following:

• White cell count at presentation > 30,000 for B-cell lineage and > 100,000 for T-cell lineage.
• Presence of any high-risk cytogenetic abnormalities such as t (9;22), t (1;19), t (4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.
• Failure to achieve complete remission (CR) after four weeks of induction therapy.
• Persistence or recurrence of MRD on therapy.
• Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician.
• Other high-risk features not defined above.
• Complete second remission (CR2).
• Primary refractory or relapsed ALL with MRD disease after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy.

III. Other acute leukemias:

Leukemias of ambiguous lineage or of other types (e.g. blastic plasmacytoid dendritic cell neoplasm) with less than 5% blasts by BM morphology. Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in ≤ 5% of cells are eligible.

IV. Myelodysplastic Syndrome (MDS) / Myeloproliferative Disorders (MPD) other than myelofibrosis:

• International prognostic scoring system (IPSS) risk score of INT-2 or high risk at the time of diagnosis.
• Any IPSS risk category if life-threatening cytopenia(s) exists.
• Any IPSS risk category with karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia.
• MDS/ myeloproliferative disorder overlap syndromes without myelofibrosis.
• MDS/ MPD patients must have less than 10% bone marrow myeloblasts and ANC ≥ 0.2 (growth factor supported if necessary) at transplant work-up.

V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:

• Eligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR.
• Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm.
• Eligible patients with HL will be those without progression of disease (POD) after salvage chemotherapy with no single lesion ≥ 5 cm.

VI. Inherited Metabolic Disorders [also see EBMT Handbook for discussion on patient eligibility for allogeneic transplant; in general, patients are considered early in the disease course, before they develop neurologic symptoms (46)]:

• Hurler Syndrome
• Hunter (MPS 2 - early disease)
• Sly syndrome (MPSVIII)
• α-Mannosidosis
• X- ALD
• Osteopetrosis
• Metachromatic Leukodystrophy
• Globoid (GLD)

VII. Non-Malignant disorders (other) [also see EBMT Handbook for criteria for transplant (46)]

• Hemoglobinopathies
• Bone Marrow Failure syndromes
• Immunodeficiencies, including HLH

Organ Function and Performance Status Criteria:

• Karnofsky or Lansky score ≥ 70% (see Appendix)
• Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia).
• ALT ≤ 3 x upper limit of normal.
• Pulmonary function (spirometry and corrected DLCO) ≥ 50% predicted (corrected for hemoglobin) .
• Left ventricular ejection fraction ≥ 50%.
• Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) less than or equal to 7.
• Renal: serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.

Normal GFR in Children and Young Adults (Age) : Mean GFR +- SD (mL/min/1.73 m2)

1 week: 40.6 + / - 14.8 2-8 weeks: 65.8 + / - 24.8 >8 weeks: 95.7 + / - 21.7 2-12 years: 133.0 + / - 27.0 13-21 years (males): 140.0 + / - 30.0 13-21 years (females: 126.0 + / - 22.0

GFR, glomerular filtration rate; SD, standard deviation greater than 2 years old: Normal GFR is 100 mL/ min. Infants: GFR must be corrected for body surf ace area.

For metabolic diseases: disease status to be evaluated according to EBMT Handbook [45].

Graft Criteria

CB units will be selected according to the current MSKCC unit selection algorithm. High resolution 8 allele HLA typing and recipient HLA antibody profile will be performed. Cord unit selection will occur based on HLA-match, total nucleated cell (TNC) and CD34+ cell dose adjusted per patient body weight. The cord bank of origin will also be considered. Donor specific HLA antibodies, if present, will also be taken into consideration and may influence the selection of the graft. CB graft will consist of one or two CB units (CBU) based on MSKCC selection algorithm.

• Each CB unit must be at least 3/8 HLA-matched to the patient considering high-resolution 8-allele HLA typing.
• For malignant diseases follow MSKCC CBU selection algorithm
• For non-malignant diseases, CBU will be required to have > 5 x 107 TNC/kg; high HLA allele level match is preferable

Exclusion Criteria

• Inadequate performance status/ organ function.
• Advanced metabolic disease (EBMT handbook).
• Active CNS leukemic involvement.
• Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.
• Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis.
• Autologous stem cell transplant within the preceding 6 months.
• Any prior allogeneic stem cell transplant.
• Active and uncontrolled infection (bacterial/fungal/viral) at time of transplantation.
• HIV infection.
• Seropositivity for HTLV-1.
• Pregnancy or breast feeding.
• Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria Cancio, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Maria I Cancio, MD

Role: CONTACT

canciom@mskcc.org

212-639-2446

Jaap Jan Boelens, MD, PhD

Role: CONTACT

boelensj@mskcc.org

212-639-3643

Facility Contacts

Maria Cancio, MD

Role: primary

212-639-2446

E.

Role: backup

Related Links

http://www.mskcc.org

Memorial Sloan Kettering Cancer Center

Other Identifiers

20-480

Identifier Type: -

Identifier Source: org_study_id